Meletios Dimopoulos

1:19
Moving towards a daratumumab standard of care in MM
Meletios Dimopoulos
1:44
OPTIMISMM: benefits of a new triplet therapy for MM patients relapsing on lenalidomide
Meletios Dimopoulos
2:43
Imaging modalities and treatment breakthroughs in myeloma bone disease
Meletios Dimopoulos
1:32
iNNOVATE results: a prospective new standard of care for Waldenström’s
Meletios Dimopoulos
1:56
Randomized trials of pomalidomide combinations for MM
Meletios Dimopoulos
6:23
Exciting new therapy for Waldenström’s macroglobulinemia: ibrutinib plus rituximab
Meletios Dimopoulos
1:21
Highlights on interesting data presented at COMy 2017
Meletios Dimopoulos
1:31
How effective are current drug treatments for patients with myeloma kidney disease?
Meletios Dimopoulos
1:56
Effective antibody therapy and updates from the POLLUX and CASTOR trials
Meletios Dimopoulos
1:37
Which is the best combination therapy in relapsed and refractory multiple myeloma?
Meletios Dimopoulos
1:50
Which treatments are currently available for relapsed and refractory myeloma treatment?
Meletios Dimopoulos
5:36
Daratumumab shows remarkable benefit in relapsed or refractory multiple myeloma in the POLLUX trial
Meletios Dimopoulos
The content of VJHemOnc is intended for healthcare professionals